NASDAQ
13.48USD
-0.26 (-1.89%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
322.5M
P/E
—
EPS
—
Beta
-0.21
52W range
8.7-26.185
Day range
13.30–14.03
Open
13.95
Prev close
13.74
Volume
696.1K
Avg volume
287.5K
Dividend
0.00
IPO
2014-10-22
https://seekingalpha.com/article/4924980-dbv-technologies-viaskins-fda-path-still-leaves-room-for-more-upside · 7/23/2026+0.80
https://www.defenseworld.net/2026/03/15/dbv-technologies-nasdaqdbvt-shares-gap-up-heres-what-happened.html · 3/15/2026+0.40
https://www.defenseworld.net/2026/02/07/dbv-technologies-s-a-nasdaqdbvt-receives-consensus-rating-of-moderate-buy-from-brokerages.html · 2/7/2026+0.60
https://www.benzinga.com/news/health-care/25/12/49447439/peanut-allergy-patch-for-kids-dbv-technologies-advances-toward-fda-filing · 12/17/2025+1.00
https://seekingalpha.com/article/4853887-dbv-technologies-s-a-dbvt-discusses-positive-phase-iii-vitesse-trial-results-for-peanut · 12/17/2025
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
